Thijssen Lab

Research focus

ERC Starting Grant · 2023

Applying novel single-cell multiomics to elucidate leukaemia cell plasticity in resistance to targeted therapy

Novel targeted therapies are increasingly applied against a wide range of cancers. Although such agents can induce cures, most patients suffer from relapsed disease. Acute myeloid leukaemia (AML) is a prime example of a deadly disease, but we have a chance to dramatically improve outcomes if we can better understand resistance mechanisms against targeted agents that are transforming AML treatment, such as the BCL2 inhibitor venetoclax. AML is characterised by profound alterations in the epigenome that are correlated with poor survival. I therefore hypothesise that targeted drug pressure induces epigenetic plasticity that allows cancer cells to sample alternate chromatin or transcriptional…

From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.